AI-Developed Coronavirus Vaccine Shows Promise in First Human Trial

A vaccine designed to fight future coronavirus threats before they emerge has successfully passed its first human clinical trial.

Researchers from the University of Cambridge and biotechnology company DIOSynVax have developed an experimental "universal" coronavirus vaccine that aims to protect against an entire family of related viruses rather than a single strain. The early-stage study found the vaccine was safe and well-tolerated in 39 healthy volunteers, with no significant side effects reported.

Unlike conventional vaccines that target viruses already circulating in humans, the new approach focuses on shared features across the Sarbecovirus family, which includes the virus behind COVID-19, SARS, and several related coronaviruses currently circulating in bats.

The vaccine uses an artificial intelligence-designed "super-antigen"—a single engineered protein created by analyzing genetic information from multiple coronaviruses. Instead of training the immune system against one virus, the super-antigen teaches it to recognize characteristics common to many related viruses, including strains that may emerge in the future.

Researchers say this could help break the cycle of constantly updating vaccines to keep pace with new variants. Current vaccines often need reformulation as viruses evolve, but a universal vaccine could potentially provide broader and longer-lasting protection.

The trial showed that participants developed immune responses not only against known human coronaviruses but also against related bat viruses that have not yet crossed into humans. This suggests the vaccine may offer protection against future spillover events that could trigger new outbreaks.

Another unique aspect of the study was the delivery method. Instead of a traditional needle injection, the vaccine was administered using a needle-free microfluidic jet system that delivers the vaccine through the skin using high-pressure fluid. Researchers believe this approach could improve vaccine acceptance and simplify mass vaccination campaigns.

Scientists caution that the vaccine remains in the early stages of development. Larger Phase 2 trials are planned to evaluate its effectiveness in a broader population and confirm whether it can generate strong, wide-ranging protection.

If future studies are successful, the technology could represent a major shift in pandemic preparedness, allowing scientists to develop vaccines that anticipate viral evolution rather than react to it after outbreaks begin.

REFERENCE: Alasdair PS Munro, Matteo Ferrari, Rebecca Kinsley, Daniel Egan, Sneha Vishwanath, Thomas Bower, Andrew Chan, Matthew Davies, Joanne Marie M. Del Rosario, Ron Moss, Yvanne Enever, Benedict Asbach, Ralf Wagner, Rachel Bousfield, Krishna Chatterjee, Victoria Cornelius, Saul N. Faust, Jonathan L. Heeney. A phase I, needle free, dose escalation clinical trial of pEVAC-PS, a candidate pan-Sarbecovirus Vaccine. Journal of Infection, 2026; 92 (6): 106759 DOI: 10.1016/j.jinf.2026.106759